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THE POTENT oncogenic compound ethyl-
nitrosourea (ENU) selectively induces a
high incidence of neurogenic neoplasms
in the offspring of pregnant rats after i.v.
administration late ingestation (Ivankovic
& Druckrey, 1968; Koestner et al., 1971).
The ENU-treated offspring survive a
latency period of 100 to several hundred
days and then succumb either to malignant
gliomas of the brain or spinal cord, or to
malignant Schwannomas located predomi-
nantly in Cranial Nerve V or spinal nerve
roots. Whether these gliomas and Schwan-
nomas are immunogenic, and whether the
gliomas, located in the relativelv immuno-
logically privileged brain (Scheinberg etal.,
1964, 1965) areprotectedfromimmunesur-
veillance comprise two questions pertain-
ing to the role of immunity in the patho-
genesis of brain tumours. Among several
experimental approaches to these ques-
tions, one consists of immunizing against
carcinogenesis (Prehn, 1961) i.e., inocu-
lating the offspring of ENU-treated rats
with glioma or Schwannoma antigens to
determine whether this type ofimmuniza-
tion increases the lifespan, or reduces the
incidence of tumours, in susceptible ani-
mals. The feasibility of attempting to
immunize against chemical carcinogenesis
in animal tumour systems was established
by the successful work of Taranger et al.
(1 972) who demonstrated that immuniza-
tion ofFischer rats with syngeneic bladder-
tumour cells significantly decreased the
incidence of papillomas induced by sub-
sequent implantation of methylcholan-
threne in the bladder.Encouraged by these
observations, we investigated whether
immunization with tumour cells during the
latent period affects the process of ENU
neuro-oncogenesis in rats, and present
our findings in this report.
Twenty pregnant F-344 rats (Tyler's
Laboratories, Bellevue, Washington) re-
ceived single i.v. injections of ENU (gift
of Dr T. Lloyd Fletcher, University of
Washington) at 50 mg/kg body wt between
the 16th and 19th days ofgestation (Koest-
ner et al., 1971). The 181 offspring (90
males and 91 females) at 5 weeks of age
were divided into 6 groups and immunized
as indicated in Table I.
The glioma-cell immunizing inocula
administered to Group I rats were pre-
pared from 4 separate ENU-induced syn-
geneic glioma lines, previously generated
in our laboratory by the alternate culture
and transplantation method (Benda et al.,
1971). These glioma lines originated from
a cerebral glioblastoma multiforme, a
cerebral mixed oligodendroglioma-astro-
cytoma, and 2 astrocytomas, one cerebral
and the other from spinal cord. Early-
generation stocks of the 4 glioma lines
maintained in vitro in Waymouth's
medium (Hellstrom & Hellstrom, 1971)
were washed wvith phosphate-buffered
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TABLE I.-Inmnunization treatments
Girotip Immtinizing inoctila j
I Glioma cells+CFA*
IL Schwannoma cells+CFA
III Normal glial cells+CFA
IV Normal fibroblasts+CFA
V CFA alone
VI Control (No Immunization)
* CFA Complete Freuncl's Adjuvant.
saline (PBS) dislodged witil rulbber police-
men, suspended in PBS, and counted by
means of the trypan-blue dye-exclusion
method. Concentrations were adjuLsted
and equtal portions of each glioma line
were combined to yield a final suspension
of 106 total dye-excluding cells per ml
(i.e., each ml of final suspension contained
2*5 x 105 cells ofeach ofthe 4 glioma lines).
Aliquots of 1 0 ml were stored frozen in
liquid N2 until needed; they were then
thawed, immediately suspended with 0-5
ml of complete Freund's adjuvant (CFA)
(Grand Island Biologicals, Grand Island,
New York), and injected s.c. into the right
flank of Group I animals. Each animal of
this group thereby received a single
immunization with 106 glioma cells in
CFA.
The immunizing inocula for Group II
animals were similarly prepared from early
cultures of 3 separate ENU-induced malig-
nant Schwannomas, 2 from the trigeminal
nerve and 1 from the cauda equina. The
1ml aliquots administered to each rat of
this group contained 3-33 x 105 cells of
each Schwannoma cell line.
Normal glial cell (Group III) and fibro-
blast (Group IV) suspensions at concentra-
tions of 106 cells in Iml aliquots were
prepared from newborn rat spinal cord or
lung cultures, established and maintained
by conventional methods.
Group V animals received only a single
dose of 0 5 ml of CFA at 5 weeks of age.
Group VI served as an unimmunized con-
trol population.
Following immunization all animals
were monitored daily. After euthanasia of
moribund animals or spontaneous death,
all viscera, particularly the brain, spinal
.Males Fe'nales
21 23
16 16
14 16
17 18
11 10
11 8
'I'otal
44
32
30
35
21
19
cord, and cranial and spinal nierves, were
carefully examined in situ before removal
and fixation in I0o buffered formalin. Age
at death was recorded in days. The fixed
viscera were again carefully inspected and
sectioned. One to 2mm thick coronal
sections of the brain, and transverse sec-
tions of the spinal cord and roots, were
examined with a hand lens. This method
permitted detection of tumours 2 mm or
greater in diameter. Tumours in the brain
or spinal cord were recorded as gliomas,
and tumours in the cranial nerves, spinal
roots, or other peripheral nerves were
recorded as Schwannomas. In selected
instances microscopic sections were pre-
pared in order to ascertain the correct
location and histological diagnosis. How-
ever, only gross neoplasms are reported
(Denlinger et al., 1973).
Within the individual groups the meani
lifespan, the mean number of gliomas or
Schwannomas per rat, and the mean of
the total number of tumours per rat were
calculated. Among all the immunization
groups the means ofthese 4 variables w-ere
assessed for statistically significant dif-
ferences by an unweighted analysis of
variance, retaining sex as a second factor.
The results are presented in Table 11.
XVith respect to lifespan, number of
gliomas or number of Schwannomas per
rat, or total number of tumours per rat,
there were no differences among Groups
I-VI, no differences attributable to sex,
and no significant interaction between sex
and groups; that is, the various immuniza-
tion procedures were all without significant
effect on the outcome of ENU neuro-
oncogenesis under the conditions of this
experiment.
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TABLE II. Lifespan and tumour incidence in immunized ENU-treated rats
Immunization
group
I
(Glioma cells)
II
(Schwaninoma cells)
III
(Normal Glial cells)
IV
(Fibroblasts)
V
(CFA alone)
VI
(Control)
Sex
M
F
M & F
M
F
I & F
Number
21
23
44
16
16
32
M 14
F 16
M & F 30
M
F
M & F
M
F
M & F
17
18
35
11
10
21
WI 11
F 8
Al&F 19
Mean
lifespan
in days
+s.d.
215±6:3
254± 70
236± 69
217±46
242± 76
229± 64
229± 60
259± 64
245± 77
234± 11:3
245± 83
239± 97
226±56
221± 71
223± 62
233 ± 52
242± 86
237 ± 67
Range
115-348
138-438
Mean
gliomas
per rat
4-s.d.
1-29±-1-23
1-70±0-95
1-50±1.10
160-298 1-19±0-91
97-447 1-31 ±0-98
1 25±0 94
141-508 1-36+0 74
177-372 1-69± 1-04
1-53± 0-92
Mean
Schwannomas
per rat
-4-s.d.
0-67 + 0-86
0 39± 0-66
0-52±0-75
0-63± 0-81
0 44± 0-63
0-53±0-71
0-86±0-77
0-56± 0-51
0 70±0-64
Mean
total
tumours
per rat
±s.d.
2-10± 1-57
2-22± 1-02
2-15± 1-31
2-00±0-80
1-88±1 00
1-94±0-90
2-21±077
2-31±1-04
2-27± 093
123-549 1-12± 1-05 0-65±0.70 1-88± 1-02
135-484 1-78± 1-08 0 39±0 50 2-28±1-28
1-46± 1 10 0-51±0-60 2-09± 1-18
131-311 1 64± 0-81
132-378 130±090
1-48±0-85
161-314 1-36±0-92
115-420 1-50±0-87
1-42±0-88
073± 047
0-50±0-85
0-62±0-65
2-36±0-77
1-90±0-83
2-14±0-83
0-64± 0-81 2-27± 0 75
0-25±0-71 1-88± 1-17
0-47+075 2-11±0 97
The mean number of Schwannomas per
rat was greater in the 90 males (0.69)
than in the 91 females (0.43) (P<0 01 by
analysis of variance). Although the mean
lifespan (226 days) and mean number of
gliomas per rat (1.30) in the entire group
of males were less than in females (246
days and 1 58 gliomas respectively), these
differences were not statistically sig-
nificant.
In the whole series of 181 rats, 20 non-
neurogenic tumours were also noted:
6 renal, 4 small bowel, 2 lung, 2 breast,
2 mediastinal, 1 urinary bladder, 1 intra-
cranial meninges, 1 pituitary, and 1
testis. These were randomly distributed
among the various groups.
That no immunological effect on ENU
neuro-oncogenesis was detected in the
present study is probably explained by
the following considerations. First, with
few exceptions chemically induced immu-
nogenic neoplasms express individually
unique rather than cross-reacting trans-
plantation antigens (Herberman, 1977).
Although some investigators have demon-
strated cross-reacting antigens shared
among certain chemically induced experi-
mental tumours (Reiner & Southam, 1967;
Steele & Sjogren, 1974; Hellstrom et al.,
1978) such antigens probably do not play
a dominant role in eliciting tumoricidal
immunity in vivo (Hellstrom & Brown,
1979). It is unlikely, therefore, that our
immunizing preparations, despite being
derived from several tumours, contained
major immunogenic constituents in com-
mon with the ENU-induced neoplasms
that arose in our immunized rats. Second,
regarding thegliomas, their locationwithin
the relatively immunologically privileged
CNS parenchyma (Scheinberg et al., 1964,
1965) probably protected them from expo-
sure to cellular and humoral immune
elements. Third, the carcinogenic action
of ENU takes place late in foetal develop-
ment, a time at which immunological
tolerance to potential tumour-associated
transplantation antigens could evolve.
Fourth, our methods may not have pre-
sented sufficient antigenic material to
induce effective immunity in the tumour-
developing rats. Fifth, since many chemi-
cal carcinogens including methylnitro-
sourea, which is closely related to ENU
(Parmiani et al., 1971) display immuno-
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suppressive activity, there is a distinct
possibility that ENU vitiated the capacity
of host animals to respond immunologic-
ally to tumour development. Sixth, the
immunogenicity of ENU-induced tumours
may be so weak as to be undetectable.
To what degree these factors indi-
vidually affected our experimental results
is open to speculation. All probably con-
tributed but, in our view, the immuno-
genicity of ENU-induced rat tumours is
the most important consideration. Rain-
bird & Ridley (1977) evaluated the
immunogenic strength of 6 ENU-induced
rat Schwannomas in in vivo tumour-
rejection assays (Sjogren, 1965) and deter-
mined that only 1 of these 6 Schwanno-
mas was immunogenic. On the other hand,
Cornain et al. (1975) claimed to have
demonstrated with similar methods that
2 ENU-induced rat tumours, one glioma
and one Schwannoma, both manifested
low immunogenicity. However, no sup-
porting data from in vivo tests accom-
panied this claim. In our laboratory,
ongoing investigations of this type have
revealed that only 1 of 5 ENU-induced
gliomas elicits detectable transplantation
immunity in vivo (unpublished observa-
tions). In concert with the findings on
Schwannomas (Rainbird & Ridley, 1977)
these observations suggest that the inci-
dence of tumour-rejection antigens in
transplantable ENU-induced neurogenic
tumours, gliomas as well as Schwannomas,
is low. Itis likely thattheincidence ofsuch
antigens is similarly low in autochthonous
ENU-induced gliomas and Schwannomas,
indeed, low enough to explain adequately
why the immunological measures reported
in this communication influenced neither
the latency nor the incidence of tumours
in ENU neuro-oncogenesis in the rat.
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